Antibody-Mediated Rejection Market Insight, Epidemiology and Market Forecast Report 2021-2030 –

Antibody-Mediated Rejection Market Insight, Epidemiology and Market Forecast Report 2021-2030 –

Antibody-Mediated Rejection Market Insight, Epidemiology and Market Forecast Report 2021-2030 –

DUBLIN–(BUSINESS WIRE)–The “Antibody-Mediated Rejection – Market Insight, Epidemiology and Market Forecast 2030” drug pipelines has been added to’s offering.

The AMR market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted AMR symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current AMR symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

AMR Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the AMR market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The AMR market report gives a thorough understanding of AMR symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides AMR symptoms of treatment algorithms and treatment guidelines for AMR symptoms in the US, Europe, and Japan.

In concordance with these views, treatment protocols for AMR use permutations of a multiple-prong approach that include (1) the suppression of the T-cell dependent antibody response, (2) the removal of donor reactive antibody, (3) the blockade of the residual alloantibody, and (4) the depletion of naive and memory B-cells. Although all published protocols report a variable rate of success, a major weakness of all current protocols is the lack of effective anti-plasma cell agents.

AMR Epidemiology

The AMR symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total incident cases of AMR is increasing by 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted AMR symptoms epidemiology segmented as the Transplant incidence of AMR, and Antibody-Mediated Rejection cases.

AMR Emerging Drug

Clazakizumab: CSL Behring

Clazakizumab is a potent, monoclonal antibody that binds to and inhibits IL-6, an important driver of the inflammatory response that is known to play a key role in transplant rejection. While advances in transplantation techniques and therapies have markedly improved short-term success rates over the past 15-20 years, long-term graft survival remains one of the greatest challenges, with AMR recognized as the most common cause of long-term kidney allograft failure.

Imlifidase: Hansa Biopharma

Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically target IgG and inhibits IgG-mediated immune response. Using imlifidase is a novel approach to eliminate pathogenic IgG. It has a rapid onset of action, cleaving IgG-antibodies, and inhibiting their reactivity within hours after administration.

AMR Market Outlook

The AMR market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted AMR market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of AMR market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

According to the publisher, the AMR market in 7MM is expected to grow in the study period 2017-2030.

The primary aims of nearly all therapeutic approaches for AMR are removing circulating DSA and reducing DSA production. In this sense, the strongholds for contemporary treatment of AMR are represented by plasma exchange (PLEX) and IVIG, although neither of these has FDA approval. Over the last decade, the complement system has attracted increasing attention as an important contributor to AMR. The main goal of using complement inhibitors is to avoid the downstream damage to the allograft from DSA. Eculizumab is one such therapy that results in terminal complement blockade as a monoclonal antibody targeting C5.

Key Findings

This section includes a glimpse of the AMR market in 7MM. The market size of AMR in the seven major markets was USD 90.22 million in 2020.

AMR Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers AMR market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

AMR Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase II and III stages. It also analyses AMR key players involved in developing targeted therapeutics.

Major players include CSL Behring, Hansa Biopharma, and Viela Bio.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for AMR emerging therapies.

Companies Mentioned

  • Hansa Biopharma
  • CSL Behring

For more information about this drug pipelines report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900